Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.
about
Recent advances in clinical applications of circulating cell-free DNA integrityNext generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patientsDNA studies using atomic force microscopy: capabilities for measurement of short DNA fragmentsAbnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: A review of literature.Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors.Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots.Circulating cell-free DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer.Liquid biopsy: monitoring cancer-genetics in the blood.Circulating free DNA in the management of breast cancer.Guidance for laboratories performing molecular pathology for cancer patients.High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.Multiparametric analysis of cell-free DNA in melanoma patientsThe identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in bloodKRAS mutation analysis by PCR: a comparison of two methods.A two-gene blood test for methylated DNA sensitive for colorectal cancer.A novel method for screening colorectal cancer by infrared spectroscopy of peripheral blood mononuclear cells and plasma.Associations between tumor markers and the risk of colorectal polyp recurrence in Chinese peopleA multiplex serum protein assay for determining the probability of colorectal cancer.Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-AnalysisPrognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Lymph node pooling: a feasible and efficient method of lymph node molecular staging in colorectal carcinoma.Endoscopic tattooing of early colon carcinoma enhances detection of lymph nodes most prone to harbor tumor burden.Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resectionDiagnostic and prognostic value of circulating tumor-related DNA in cancer patients.Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.Cell-free circulating DNA integrity is an independent predictor of impending breast cancer recurrence.Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome.Urine cell-free DNA integrity as a marker for early prostate cancer diagnosis: a pilot study.The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review.Circulating cell-free DNA in serum as a biomarker of colorectal cancer.Tumor-associated DNA mutation detection in individuals undergoing colonoscopy.Colorectal Cancer Blood-Based Biomarkers.Plasma DNA integrity index as a potential molecular diagnostic marker for breast cancer.Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial.Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.Circulating free DNA in plasma or serum as biomarkers of carcinogenesis in colon cancer.
P2860
Q26861681-10B09F41-D90F-4370-BB9E-32E64AC5A9A4Q28067439-19D6BFC2-A221-4701-882A-E350B84BEA9CQ28080979-20BC3613-0A66-4DE4-A82F-E1383FDC6691Q33560085-C4A0278E-32A6-4D1F-AB87-684B849BA519Q34012005-DA3C5E7A-D814-4E51-BFA9-72EEED4863E6Q34193602-DDB55243-91B7-49D0-AE92-769A630A8B3BQ34354622-52FDDD5F-6E45-4710-BC1C-C25B22013666Q34356149-BCFF66B2-833E-4E33-B7C9-89CA3CE9AC8AQ34357893-DBADA2C3-F3DB-4D22-A6D7-2B601447BBDFQ34431280-633081E8-DB72-42D6-98B7-929E280BED54Q34433513-8CCCB78F-E7C3-4F49-A401-DB50C1377ABEQ34499759-E6D4938D-E746-4324-861D-17667629D1B0Q34730350-3D03AE10-6A00-441C-9579-19B2D6ECF138Q34876437-E7F058AD-A247-444F-87CE-4E02AE3E356CQ35558499-DADABA9D-FDAB-401F-BC05-C2E15FC3E585Q35674871-112816B7-C127-44B2-94C8-FB10742B42C5Q35791820-030B84CF-3D6B-4762-AEF4-BFA25AF341F2Q36206469-48DA7CE9-F437-4927-B22F-E135833C0198Q36400527-4642873D-A6C8-4064-9854-6402A99952A7Q36865058-7CAFB763-1D8B-4B3D-9FE1-3334B4C181A6Q37015727-749B348C-A2AF-446C-9CE6-BF8237FDED7EQ37061376-8FE16B61-92D3-4228-A41D-A6C882C217EBQ37587123-675BE20C-D7CF-47CF-BF6A-A0AABEB1E443Q37607246-BFA2EEF6-9A35-400E-A716-2582946446A4Q37715050-3E1094CA-AAF8-47BB-B970-201B2E7C1778Q38152782-3BD63A0A-0B95-43A6-AB6B-7A900583AAC2Q38191574-9DC38290-E226-40AD-9CF2-4B65C5AC5D3DQ38717500-75D65011-E75E-4338-A4F0-1C814CCD2C66Q39051797-7EEA4358-E536-4029-8BD5-F4EF6413533DQ40043175-6B24A36D-A483-4076-B986-F65E8801ED8DQ41332109-8737679D-328D-4C3F-86D2-898B2A2E9621Q41672565-3933B161-8C0B-4125-918D-869200C3701EQ42643973-E4B44292-DE5B-42D7-89B3-BFAFF3AD067EQ45799429-709E3CAE-20A9-4C85-AC25-F827332DBF7EQ46393954-310B5564-464A-453F-A674-41BA37266BA0Q46578913-3414ABCA-71FE-4CD6-A3FF-461C99432F87Q46790693-665A6394-E919-47EE-B9BB-A45AD5B66D1DQ48105658-2FA4C9A6-FFFB-4047-8F2D-94D590D1C96CQ48230033-D9AA1C55-2339-44AF-9467-180280263EE5Q48486711-D2952C25-CE0F-4238-B0F7-B63142AE6F75
P2860
Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Circulating tumour markers can ...... s, benign polyps, and cancers.
@ast
Circulating tumour markers can ...... s, benign polyps, and cancers.
@en
type
label
Circulating tumour markers can ...... s, benign polyps, and cancers.
@ast
Circulating tumour markers can ...... s, benign polyps, and cancers.
@en
prefLabel
Circulating tumour markers can ...... s, benign polyps, and cancers.
@ast
Circulating tumour markers can ...... s, benign polyps, and cancers.
@en
P2093
P2860
P356
P1476
Circulating tumour markers can ...... s, benign polyps, and cancers.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.230
P407
P577
2011-06-28T00:00:00Z